Right greater splanchnic nerve Ablation useful treatment option for managing HFpEF: Study

The findings of the study are as follows:

• There were no adverse events related to the blockade of the nerve during 12-month follow-up but three patients had significant peri-procedural adverse events related to the surgical procedure itself.
• At 3 months post-GSN ablation, patients demonstrated a reduction in 20 W exercise PCWP when compared to baseline, which carried over to peak exercise.
• At 12 months, improvements were seen in NYHA class and quality of life assessed with the Minnesota Living with Heart Failure Questionnaire.

The researchers concluded that in this first-in-human study, GSN ablation in HFpEF proved to be feasible, with a suggestion of reduced cardiac filling pressure during exercise, improved quality of life and exercise capacity.

Reference:

Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: a first-in-human clinical trial by Málek F et. al published in the European Journal of Heart Failure.

DOI: 10.1002/ejhf.2209